A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients

J Trauma. 1995 Feb;38(2):233-6. doi: 10.1097/00005373-199502000-00015.


Objective: To evaluate the effects of recombinant human erythropoietin (r-HuEPO) in attempting to prevent anemia in acutely burned patients.

Design: Prospective double-blind randomized study of 40 patients.

Methods: Patients with burns from 25% to 65% total body surface were enrolled. r-HuEPO or a placebo was begun within 72 hours of admission. Cell blood count, reticulocyte counts, transfusion requirements, and blood loss were measured. Comparison was carried out by the unpaired t test.

Main results: There was no statistically significant difference in hemoglobin, hematocrit, reticulocyte count, ferritin, serum iron, total iron blinding capacity, or transfusion requirements. In patients with burns from 25% to 35%, the reticulocyte counts were statistically significantly higher.

Conclusion: In our work the administration of r-HuEPO in acutely burned patients did not prevent the development of postburn anemia or decrease transfusion requirements. Increased erythropoiesis in smaller burns (25% to 35%) was observed and may indicate a reason for further study.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anemia / etiology
  • Anemia / prevention & control*
  • Blood Transfusion
  • Burns / complications*
  • Burns / physiopathology
  • Double-Blind Method
  • Erythropoietin / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Recombinant Proteins / therapeutic use
  • Reticulocyte Count


  • Recombinant Proteins
  • Erythropoietin